Does ruxolitinib prolong the survival of patients with myelofibrosis?
Author:
Affiliation:
1. Hematology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; and
2. Hemotherapy Department, Hospital Clínic, Barcelona, Spain
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/129/7/832/1401692/blood731604.pdf
Reference33 articles.
1. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment;Cervantes;Blood,2009
2. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT);Mesa;Leuk Res,2007
3. Genetic and epigenetic alterations of myeloproliferative disorders;Milosevic;Int J Hematol,2013
4. How I treat myelofibrosis;Cervantes;Blood,2014
5. Improving survival trends in primary myelofibrosis: an international study;Cervantes;J Clin Oncol,2012
Cited by 84 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Janus Kinases and Autoimmunity: Bridging Pathways to Therapy;International Journal of Drug Discovery and Pharmacology;2024-06-05
2. Methodological challenges in the development of endpoints for myelofibrosis clinical trials;The Lancet Haematology;2024-05
3. Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation;European Journal of Haematology;2024-02-09
4. Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials;HemaSphere;2023-10-27
5. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia;British Journal of Haematology;2023-09-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3